1-2 of 2
Deyaa Adib, MD
Close
Save search
Sort by
Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Free
Gilles Salles, MD PhD, Hervé Tilly, MD, Aristeidis Chaidos, MD PhD, Pam McKay, MD, Tycel J. Phillips, MD, Sarit E Assouline, MD MSc, Connie Lee Batlevi, MDPhD, Philip Campbell, MBBS, Vincent Ribrag, MD, Gandhi Laurent Damaj, MD PhD, Michael Dickinson, DMed Sci, Wojciech Jurczak, MD PhD, Maciej Kaźmierczak, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, John A. Radford, MD FMedSci, Anna Schmitt, MD, Jennifer Whalen, DHS, Anthony Hamlett, PhD, Beth Kamp, PharmD, Deyaa Adib, MD, Franck Morschhauser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-137245
Published: 2020
Journal Articles

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

Free
David Proudman, MSc,MPH, Dave Nellesen, PhD, Deepshekhar Gupta, MS, Deyaa Adib, MD, Jay Yang, PhD, Michael Keith, PhD PharmD, Khalid Mamlouk, PharmD, BCOP
Journal: Blood
Blood (2020) 136 (Supplement 1): 16.
https://doi.org/10.1182/blood-2020-137772
Published: 2020